Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

DELINEATION OF AN IMMUNODOMINANT AND HUMAN T-CELL LYMPHOTROPIC VIRUS (HTLV)-SPECIFIC EPITOPE WITHIN THE HTLV-I TRANSMEMBRANE GLYCOPROTEIN BLOOD Hadlock, K. G., Goh, C. J., BRADSHAW, P. A., Perkins, S., Lo, J., Kaplan, J. E., Khabbaz, R., Foung, S. K. 1995; 86 (4): 1392-1399

Abstract

Antibody reactivity to the transmembrane region of human T-cell lymphotropic virus type I (HTLV-I) envelope, gp21, is observed in virtually all individuals infected with HTLV-I or HTLV-II. Recombinant proteins encoding selected portions of gp21 are described and used to define two immunogenic regions. The first epitope (designated GD21-I) contains amino acids 361 to 404 of the HTLV-I envelope and reacted with all of 54 sera from HTLV-I- and HTLV-II-infected individuals. The second epitope (designated BA21) expresses amino acids 397 to 430 of the HTLV-I envelope and was recognized by 33 of 54 HTLV antisera. To determine the specificity of GD21-I and BA21, sera from 17 HTLV-negative individuals with nonspecific reactivity to p21E were tested. None of these sera reacted with GD21-I, but 16 of 17 sera reacted with BA21. With virtually complete reactivity to sera from HTLV-infected individuals and no reactivity to sera from p21E-reactive uninfected individuals, GD21-I will be useful in immunoassays for the detection of HTLV infection.

View details for Web of Science ID A1995RN46700022

View details for PubMedID 7632947